Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Department of Endocrinology, Affiliated Hospital of Jiangnan University, Wuxi, China.
J Diabetes. 2024 Apr;16(4):e13536. doi: 10.1111/1753-0407.13536.
It is not clear whether there are differences in glycemic control between the Equil patch and the MMT-712 insulin pump. Our objective was to compare two types of insulin pumps in the treatment of type 2 diabetes mellitus (T2DM), using continuous glucose monitoring (CGM) metrics and profiles.
This was a randomized case-crossover clinical trial. Participants were hospitalized and randomly allocated to two groups and underwent two types of insulin pump treatments (group A: Equil patch-Medtronic MMT-712 insulin pump; group B: Medtronic MMT-712-Equil patch insulin pump) separated by a 1-day washout period. Glycemic control was achieved after 7-8 days of insulin pump therapy. Each patient received CGM for 5 consecutive days (from day 1 to day 5). On day 3 of CGM performance, the Equil patch insulin pump treatment was switched to Medtronic MMT-712 insulin pump treatment at the same basal and bolus insulin doses or vice versa. CGM metrics and profiles including glycemic variability (GV), time in range (TIR, 3.9-10.0 mmol/L), time below range (TBR, <3.9 mmol/L), time above range (TAR, >10.0 mmol/L), and postprandial glucose excursions, as well as incidence of hypoglycemia.
Forty-six T2DM patients completed the study. There was no significant difference in parameters of daily GV and postprandial glucose excursions between the Equil patch insulin pump treatment and the Medtronic insulin pump treatment. Similarly, there was no between-treatment difference in TIR, TBR, and TAR, as well as the incidence of hypoglycemia.
The Equil patch insulin pump was similar to the traditional MMT-712 insulin pump in terms of glycemic control. Equil patch insulin pump is a reliable tool for glycemic management of diabetes mellitus.
目前尚不清楚 Equil 贴片和 MMT-712 胰岛素泵在血糖控制方面是否存在差异。我们的目的是使用连续血糖监测（CGM）指标和图谱比较两种类型的胰岛素泵在 2 型糖尿病（T2DM）治疗中的作用。
这是一项随机病例交叉临床试验。参与者住院并随机分为两组，并接受两种类型的胰岛素泵治疗（A 组：Equil 贴片-美敦力 MMT-712 胰岛素泵；B 组：美敦力 MMT-712-Equil 贴片胰岛素泵），其间有 1 天的洗脱期。在胰岛素泵治疗 7-8 天后达到血糖控制。每位患者接受 CGM 连续 5 天（第 1 天至第 5 天）。在 CGM 性能的第 3 天，在相同的基础和推注胰岛素剂量下将 Equil 贴片胰岛素泵治疗切换为美敦力 MMT-712 胰岛素泵治疗，或者反之亦然。CGM 指标和图谱包括血糖变异性（GV）、血糖达标时间（TIR，3.9-10.0mmol/L）、血糖低于目标范围时间（TBR，<3.9mmol/L）、血糖高于目标范围时间（TAR，>10.0mmol/L）和餐后血糖波动，以及低血糖的发生率。
46 例 T2DM 患者完成了研究。Equil 贴片胰岛素泵治疗与美敦力胰岛素泵治疗之间的日常 GV 和餐后血糖波动参数无显著差异。同样，TIR、TBR 和 TAR 以及低血糖发生率也没有治疗间差异。
在血糖控制方面，Equil 贴片胰岛素泵与传统的 MMT-712 胰岛素泵相似。Equil 贴片胰岛素泵是糖尿病血糖管理的可靠工具。
